Manufacturers Life Insurance Company, The Prothena Corp Public LTD CO Transaction History

Manufacturers Life Insurance Company, The

  • $108 Billion
  • Q3 2024

A detailed history of Manufacturers Life Insurance Company, The transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Manufacturers Life Insurance Company, The holds 86,071 shares of PRTA stock, worth $1.09 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
86,071
Previous 82,908 3.82%
Holding current value
$1.09 Million
Previous $1.71 Million 15.9%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$16.73 - $24.79 $52,916 - $78,410
3,163 Added 3.82%
86,071 $1.44 Million
Q2 2024

Aug 14, 2024
BUY
$19.54 - $26.15 $6,389 - $8,551
327 Added 0.4%
82,908 $1.71 Million
Q1 2024

May 14, 2024
SELL
$24.75 - $40.66 $75,264 - $123,647
-3,041 Reduced 3.55%
82,581 $2.05 Million
Q4 2023

Feb 13, 2024
BUY
$32.31 - $52.32 $116,025 - $187,881
3,591 Added 4.38%
85,622 $3.11 Million
Q3 2023

Nov 15, 2023
BUY
$47.3 - $70.6 $786,173 - $1.17 Million
16,621 Added 25.41%
82,031 $3.96 Million
Q2 2023

Aug 11, 2023
BUY
$48.26 - $78.59 $499,394 - $813,249
10,348 Added 18.79%
65,410 $4.47 Million
Q1 2023

May 15, 2023
BUY
$46.97 - $58.27 $89,430 - $110,946
1,904 Added 3.46%
56,966 $2.76 Million
Q4 2022

Aug 11, 2023
BUY
$52.05 - $65.0 $105,713 - $132,015
2,031 Added 3.83%
55,062 $3.32 Million
Q4 2022

Feb 13, 2023
BUY
$52.05 - $65.0 $105,713 - $132,015
2,031 Added 3.83%
55,062 $3.32 Million
Q3 2022

Aug 11, 2023
SELL
$25.16 - $60.63 $7,673 - $18,492
-305 Reduced 0.57%
53,031 $3.22 Million
Q3 2022

Nov 03, 2022
SELL
$25.16 - $60.63 $7,673 - $18,492
-305 Reduced 0.57%
53,031 $3.17 Million
Q2 2022

Aug 11, 2023
SELL
$22.73 - $39.98 $29,708 - $52,253
-1,307 Reduced 2.39%
53,336 $1.45 Million
Q2 2022

Aug 15, 2022
SELL
$22.73 - $39.98 $29,708 - $52,253
-1,307 Reduced 2.39%
53,336 $1.44 Million
Q1 2022

Aug 11, 2023
SELL
$30.27 - $49.22 $70,317 - $114,338
-2,323 Reduced 4.08%
54,643 $2 Million
Q1 2022

May 20, 2022
BUY
$30.27 - $49.22 $1.13 Million - $1.83 Million
37,277 Added 214.66%
54,643 $2 Million
Q4 2021

Feb 16, 2022
BUY
$42.11 - $73.26 $3,495 - $6,080
83 Added 0.48%
17,366 $858,000
Q3 2021

Nov 12, 2021
SELL
$48.2 - $78.89 $66,082 - $108,158
-1,371 Reduced 7.35%
17,283 $1.23 Million
Q2 2021

Aug 12, 2021
BUY
$21.63 - $57.65 $30,909 - $82,381
1,429 Added 8.3%
18,654 $959,000
Q1 2021

May 03, 2021
SELL
$11.0 - $28.24 $20,724 - $53,204
-1,884 Reduced 9.86%
17,225 $433,000
Q4 2020

Feb 12, 2021
BUY
$10.12 - $13.94 $7,589 - $10,455
750 Added 4.09%
19,109 $229,000
Q2 2020

Aug 10, 2020
SELL
$9.56 - $12.51 $64,596 - $84,530
-6,757 Reduced 26.9%
18,359 $189,000
Q1 2020

May 15, 2020
BUY
$7.54 - $15.77 $9,432 - $19,728
1,251 Added 5.24%
25,116 $269,000
Q4 2019

Feb 14, 2020
SELL
$7.48 - $17.01 $14,511 - $32,999
-1,940 Reduced 7.52%
23,865 $308,000
Q2 2019

Aug 14, 2019
SELL
$8.85 - $12.49 $4,973 - $7,019
-562 Reduced 2.13%
25,805 $273,000
Q1 2019

May 13, 2019
BUY
$10.32 - $14.49 $143,231 - $201,106
13,879 Added 111.14%
26,367 $320,000
Q4 2018

Feb 14, 2019
SELL
$8.73 - $13.74 $125,144 - $196,962
-14,335 Reduced 53.44%
12,488 $129,000
Q3 2018

Nov 14, 2018
SELL
$12.7 - $15.79 $40,398 - $50,227
-3,181 Reduced 10.6%
26,823 $351,000
Q2 2018

Aug 14, 2018
BUY
$10.99 - $44.21 $22,364 - $89,967
2,035 Added 7.28%
30,004 $437,000
Q1 2018

May 15, 2018
SELL
$27.95 - $45.04 $8,440 - $13,602
-302 Reduced 1.07%
27,969 $1.03 Million
Q4 2017

Feb 08, 2018
BUY
$35.44 - $63.76 $8,895 - $16,003
251 Added 0.9%
28,271 $1.06 Million
Q3 2017

Nov 14, 2017
BUY
$53.83 - $67.75 $1.51 Million - $1.9 Million
28,020
28,020 $1.82 Million

Others Institutions Holding PRTA

# of Institutions
184
Shares Held
42.7M
Call Options Held
162K
Put Options Held
102K
View Full List

About PROTHENA CORP PUBLIC LTD CO

PRTA Quotes by TradingView
  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $592M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Manufacturers Life Insurance Company, The Portfolio

Follow Manufacturers Life Insurance Company, The and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email